未经证实:探讨血清B细胞活化因子(BAFF)和肺部超声(LUS)B线在结缔组织病相关间质性肺病(CTD-ILD)中的作用,以及它们与胸部高分辨率计算机断层扫描(HRCT)上不同ILD模式的关联。
UNASSIGNED:我们通过ELISA测量了63例CTD-ILD患者[26例纤维化ILD(F-ILD),37与非纤维化ILD(NF-ILD)],30例无ILD的CTD患者,和26个健康对照。所有患者均行胸部HRCT和LUS检查。
UNASSIGNED:CTD患者的血清BAFF水平明显高于健康受试者(617.6±288.1pg/mlvs.269.0±60.4pg/ml,p<0.01)。BAFF浓度在ILD组和非ILD组之间有显着差异(698.3±627.4pg/ml与448.3±188.6pg/ml,p<0.01)。在ILD患者中,BAFF浓度与B系数显着相关(r=0.37,95%CI0.13-0.56,p<0.01),KL-6水平(r=0.26,95%CI0.01-0.48,p<0.05),和Warrick评分(r=0.33,95%CI0.09-0.53,p<0.01),尽管所有相关性都只有低至中度。B线数与Warrick评分相关(r=0.65,95%CI0.48-0.78,p<0.01),和KL-6水平(r=0.43,95%CI0.21-0.61,p<0.01)。F-ILD患者的血清BAFF浓度较高(957.5±811.0pg/mlvs.516.1±357.5pg/ml,p<0.05),KL-6水平(750.7±759.0U/ml与432.5±277.5U/ml,p<0.05),B线编号(174.1±82vs.52.3±57.5,p<0.01),和Warrick得分(19.9±4.6vs.13.6±3.4,p<0.01)与NF-ILD患者。对于BAFF,使用ROC曲线将F-ILD与NF-ILD分离的最佳临界值为408pg/ml(AUC=0.73,p<0.01),KL-6为367U/ml(AUC=0.72,p<0.05),B线编号为122(AUC=0.89,p<0.01),Warrick评分分别为14(AUC=0.87,p<0.01)。
未经证实:血清BAFF水平和LUSB系数可能是检测和评估CTD-ILD的严重程度和/或子集的有用的支持性生物标志物。如果得到证实,结合成像,血清学,超声生物标志物在CTD-ILD的治疗中可能是有益的和全面的。
UNASSIGNED: To investigate the role of serum B-cell activating factor (BAFF) and lung ultrasound (LUS) B-lines in connective tissue disease related interstitial lung disease (CTD-ILD), and their association with different ILD patterns on high resolution computed tomography (HRCT) of chest.
UNASSIGNED: We measured the levels of BAFF and KL-6 by ELISA in the sera of 63 CTD-ILD patients [26 with fibrotic ILD (F-ILD), 37 with non-fibrotic ILD (NF-ILD)], 30 CTD patients without ILD, and 26 healthy controls. All patients underwent chest HRCT and LUS examination.
UNASSIGNED: Serum BAFF levels were significantly higher in CTD patients compared to healthy subjects (617.6 ± 288.1 pg/ml vs. 269.0 ± 60.4 pg/ml, p < 0.01). BAFF concentrations were significantly different between ILD group and non-ILD group (698.3 ± 627.4 pg/ml vs. 448.3 ± 188.6 pg/ml, p < 0.01). In patients with ILD, BAFF concentrations were significantly correlated with B-lines number (r = 0.37, 95% CI 0.13-0.56, p < 0.01), KL-6 level (r = 0.26, 95% CI 0.01-0.48, p < 0.05), and Warrick score (r = 0.33, 95% CI 0.09-0.53, p < 0.01), although all correlations were only low to moderate. B-lines number correlated with Warrick score (r = 0.65, 95% CI 0.48-0.78, p < 0.01), and KL-6 levels (r = 0.43, 95% CI 0.21-0.61, p < 0.01). Patients with F-ILD had higher serum BAFF concentrations (957.5 ± 811.0 pg/ml vs. 516.1 ± 357.5 pg/ml, p < 0.05), KL-6 levels (750.7 ± 759.0 U/ml vs. 432.5 ± 277.5 U/ml, p < 0.05), B-lines numbers (174.1 ± 82 vs. 52.3 ± 57.5, p < 0.01), and Warrick score (19.9 ± 4.6 vs. 13.6 ± 3.4, p < 0.01) vs. NF-ILD patients. The best cut-off values to separate F-ILD from NF-ILD using ROC curves were 408 pg/ml for BAFF (AUC = 0.73, p < 0.01), 367 U/ml for KL-6 (AUC = 0.72, p < 0.05), 122 for B-lines number (AUC = 0.89, p < 0.01), and 14 for Warrick score (AUC = 0.87, p < 0.01) respectively.
UNASSIGNED: Serum BAFF levels and LUS B-lines number could be useful supportive biomarkers for detecting and evaluating the severity and/or subsets of CTD-ILD. If corroborated, combining imaging, serological, and sonographic biomarkers might be beneficial and comprehensive in management of CTD-ILD.